Toward gene therapy of hypertension: Experimental study on hypertensive ISIAH rats
- Autores: Repkova M.1,2, Levina A.1,2, Seryapina A.1,3, Shikina N.1,4, Bessudnova E.1,4, Zarytova V.1,2, Markel A.1,3
-
Afiliações:
- Novosibirsk State University
- Institute of Chemical Biology and Fundamental Medicine
- Institute of Cytology and Genetics
- Institute of Catalysis
- Edição: Volume 82, Nº 4 (2017)
- Páginas: 454-457
- Seção: Article
- URL: https://journals.rcsi.science/0006-2979/article/view/151336
- DOI: https://doi.org/10.1134/S000629791704006X
- ID: 151336
Citar
Resumo
TiO2-based nanocomposites were prepared to deliver oligonucleotides into cells. The nanocomposites were designed by the immobilization of polylysine-containing oligonucleotides on TiO2-nanoparticles (TiO2·PL-DNA). We showed for the first time the possibility of using the proposed nanocomposites for treatment of hypertensive disease by introducing them into hypertensive ISIAH rats developed as a model of stress-sensitive arterial hypertension. The mRNA of the gene encoding angiotensin I-converting enzyme (ACE1) involved in the synthesis of angiotensin II was chosen as a target. Administration (intraperitoneal injection and inhalation) of the nanocomposite showed a significant (by 20-30 mm Hg) decrease in systolic blood pressure when the nanocomposite contained the ACE1 gene-targeted oligonucleotide. When using the oligonucleotide with a random sequence, no effect was observed. Further development and improvement of the inhalation nanocomposite drug delivery to systemic hypertensive disease treatment promises new possibilities for clinical practice.
Palavras-chave
Sobre autores
M. Repkova
Novosibirsk State University; Institute of Chemical Biology and Fundamental Medicine
Email: markel@bionet.nsc.ru
Rússia, Novosibirsk, 630090; Novosibirsk, 630090
A. Levina
Novosibirsk State University; Institute of Chemical Biology and Fundamental Medicine
Email: markel@bionet.nsc.ru
Rússia, Novosibirsk, 630090; Novosibirsk, 630090
A. Seryapina
Novosibirsk State University; Institute of Cytology and Genetics
Email: markel@bionet.nsc.ru
Rússia, Novosibirsk, 630090; Novosibirsk, 630090
N. Shikina
Novosibirsk State University; Institute of Catalysis
Email: markel@bionet.nsc.ru
Rússia, Novosibirsk, 630090; Novosibirsk, 630090
E. Bessudnova
Novosibirsk State University; Institute of Catalysis
Email: markel@bionet.nsc.ru
Rússia, Novosibirsk, 630090; Novosibirsk, 630090
V. Zarytova
Novosibirsk State University; Institute of Chemical Biology and Fundamental Medicine
Email: markel@bionet.nsc.ru
Rússia, Novosibirsk, 630090; Novosibirsk, 630090
A. Markel
Novosibirsk State University; Institute of Cytology and Genetics
Autor responsável pela correspondência
Email: markel@bionet.nsc.ru
Rússia, Novosibirsk, 630090; Novosibirsk, 630090
![](/img/style/loading.gif)